Form 4: BioAffinity Technologies Director Roby Joyce Acquires Shares

Director Roby Joyce acquired 8,296 shares of BioAffinity Technologies common stock on June 12, 2024, through a grant of restricted shares that vest immediately.

Summary

• On June 12, 2024, Roby Joyce, a director of bioAffinity Technologies, Inc., acquired 8,296 shares of common stock.
• The acquisition was a grant of restricted shares that vest immediately.
• The price per share was $0.00.
• Following the transaction, Roby Joyce directly owns 32,831 shares of common stock.
• Roby Joyce also indirectly owns 583,130 shares through The Joyce Living Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing reporting a transaction. The acquisition itself could be seen as slightly positive, but the filing is primarily informational.

Positives

• The acquisition of shares by a director could be seen as a positive sign, indicating confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who have transactions in their company's stock. It provides transparency to the market about insider activity.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholders if it signals confidence from a company director.

Key Dates

Keywords

bioAffinity Technologies, Roby Joyce, share acquisition, Form 4, director, common stock, beneficial ownership, restricted shares, The Joyce Living Trust